These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 32861620)
1. Evaluation of the clinical use of PET/CT with Ribeiro AMB; Lima ENP; Zequi SC Urol Oncol; 2021 Jan; 39(1):73.e9-73.e18. PubMed ID: 32861620 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital. Sangiwa BA; Burger C; Ellmann A Pan Afr Med J; 2024; 48():30. PubMed ID: 39220559 [TBL] [Abstract][Full Text] [Related]
4. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603 [TBL] [Abstract][Full Text] [Related]
5. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076 [TBL] [Abstract][Full Text] [Related]
6. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [TBL] [Abstract][Full Text] [Related]
8. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
9. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
10. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332 [TBL] [Abstract][Full Text] [Related]
11. Detection Efficacy of Hybrid Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912 [TBL] [Abstract][Full Text] [Related]
12. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423 [TBL] [Abstract][Full Text] [Related]
13. Clinical value of negative Celli M; De Giorgi U; Caroli P; Di Iorio V; Fantini L; Rossetti V; Foca F; Nicolini S; Giganti M; Paganelli G; Matteucci F Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):87-94. PubMed ID: 32588090 [TBL] [Abstract][Full Text] [Related]
14. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
15. 3-Year Freedom from Progression After Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727 [No Abstract] [Full Text] [Related]
16. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446 [TBL] [Abstract][Full Text] [Related]
17. The use of Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165 [TBL] [Abstract][Full Text] [Related]
18. The role of histopathological and biochemical parameters for predicting metastatic disease on Aydos U; Çetin S; Akdemir ÜÖ; Budak FÇ; Ateş SG; Koparal MY; Gönül İI; Gülbahar Ö; Sözen S; Atay LÖ Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677 [TBL] [Abstract][Full Text] [Related]
19. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282 [TBL] [Abstract][Full Text] [Related]
20. Gallium-68-prostate-specific membrane antigen ( van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]